MEDICATION DEVELOPMENT FOR COCAINE ABUSERS

针对可卡因滥用者的药物开发

• 批准号: 8172305
• 负责人: MICHAEL J KUHAR
• 金额: $ 4.39万
• 依托单位: EMORY UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-05-01 至 2011-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8172305
• 关键词: Cocaine; Computer Retrieval of Information on Scientific Projects Database; Development; Funding; Grant; Human; Institution; Laboratories; Pharmaceutical Preparations; Phase I Clinical Trials; Research; Research Personnel; Resources; Source; Testing; Toxic effect; United States National Institutes of Health; Writing

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. RTI-336, a compound first tested and characterized in our laboratories, has been approved for Phase I clinical trials in humans. As of this writing, no toxic effects were found that preclude further study, and additional studies are planned in humans. RTI-336 would be a new medication for cocaine addicts.

这个子项目是许多研究子项目中的一个 由NIH/NCRR资助的中心赠款提供的资源。子项目和 研究者（PI）可能从另一个NIH来源获得了主要资金， 因此可以在其他CRISP条目中表示。所列机构为 研究中心，而研究中心不一定是研究者所在的机构。 RTI-336是一种首次在我们实验室进行测试和表征的化合物，已被批准用于人体I期临床试验。 截至撰写本文时，未发现任何毒性作用，无法进行进一步研究，计划在人体中进行其他研究。 RTI-336将成为可卡因成瘾者的新药物。